Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2018 2
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Innovations in the Management of Hepatocellular Carcinoma.
Rafiullah, Ali A, Mohiuddin H, Zahid U, Abushahin L. Rafiullah, et al. Among authors: abushahin l. Am J Ther. 2018 May/Jun;25(3):e362-e368. doi: 10.1097/MJT.0000000000000713. Am J Ther. 2018. PMID: 29561268 No abstract available.
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.
Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, Williams T, Abushahin L, Bridges JFP, Santry H. Cloyd JM, et al. Among authors: abushahin l. J Clin Med. 2020 Apr 15;9(4):1129. doi: 10.3390/jcm9041129. J Clin Med. 2020. PMID: 32326559 Free PMC article.
Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials.
Hejleh TA, Abushahin L, Keech J, Allen BG, Parekh KR, Furqan M, Iannettoni M, Zamba GKD, Mott SL, Clamon G. Hejleh TA, et al. Among authors: abushahin l. Anticancer Res. 2018 Sep;38(9):5247-5251. doi: 10.21873/anticanres.12849. Anticancer Res. 2018. PMID: 30194174 Free PMC article. Clinical Trial.
Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK, Perry JB, Abdul-Rahim O, Frankel AE, Cameron D, Taylor W, Rocconi RP, Abushahin L, Nelson C, Singh AP, Khushman M. Patel GK, et al. Among authors: abushahin l. J Cancer Res Ther. 2020 Jul-Sep;16(4):950-954. doi: 10.4103/jcrt.JCRT_729_18. J Cancer Res Ther. 2020. PMID: 32930150 Free article. Review.
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
Kim GP, Surinach A, Corvino FA, Cockrum P, Belanger B, Abushahin L. Kim GP, et al. Among authors: abushahin l. Future Oncol. 2020 Oct 19. doi: 10.2217/fon-2020-0902. Online ahead of print. Future Oncol. 2020. PMID: 33070660 Free article.
Stage I Squamous Cell Carcinoma of the Anus: Is Radiation Therapy Alone Sufficient Treatment?
Miller E, Nalin A, Diaz Pardo D, Arnett A, Abushahin L, Husain S, Jin N, Williams T, Bazan J. Miller E, et al. Among authors: abushahin l. Cancers (Basel). 2020 Nov 4;12(11):3248. doi: 10.3390/cancers12113248. Cancers (Basel). 2020. PMID: 33158062 Free PMC article.
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Alexandra Diaz D, Miller ED, Chen W, Frankel WL, Noonan A, Williams TM. Wolfe AR, et al. Among authors: abushahin l. Cancer Med. 2020 Jul;9(13):4711-4723. doi: 10.1002/cam4.3075. Epub 2020 May 16. Cancer Med. 2020. PMID: 32415696 Free PMC article.
Results of an educational program to promote the use of pooled instead of single-donor platelet transfusions.
Burch M, Schneider R, Barakat A, Abushahin L, Cao Y, Ewing J, Stone MJ. Burch M, et al. Among authors: abushahin l. Proc (Bayl Univ Med Cent). 2013 Jan;26(1):3-5. doi: 10.1080/08998280.2013.11928897. Proc (Bayl Univ Med Cent). 2013. PMID: 23382598 Free PMC article.
Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma.
Seyedin SN, Gannon MK, Plichta KA, Abushahin L, Berg DJ, Arshava EV, Parekh KR, Keech JC, Caster JM, Welsh JW, Allen BG. Seyedin SN, et al. Among authors: abushahin l. Front Oncol. 2020 Jul 31;10:1311. doi: 10.3389/fonc.2020.01311. eCollection 2020. Front Oncol. 2020. PMID: 32850412 Free PMC article.
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer.
Wolfe AR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-Monserrate Z, Jacob JR, Palanichamy K, Chakravarti A, Williams TM. Wolfe AR, et al. Among authors: abushahin l. Clin Cancer Res. 2020 Oct 21:clincanres.1422.2020. doi: 10.1158/1078-0432.CCR-20-1422. Online ahead of print. Clin Cancer Res. 2020. PMID: 33087331
Feedback